리스페리돈으로 교체 투여한 정신분열병 환자에서 주관적 안녕감 = The Subjective Well-Being of theSchizophrenic Patients Who SwitchedTheir Antipsychotics to Risperidone

다국어 초록 (Multilingual Abstract)

Objectives: The aim of this study was to evaluate the subjective well-being of schizophrenic patients who switched their antipsychotics to risperidone as the maintenance treatment over 24 weeks.
Methods: Thirty-one patients were evaluated using Positive and Negative Syndrome Scale (PANSS) for psychopathology and UKU side effects rating scale for drug-induced adverse events. Also the subjects were asked to score the 10 items self-rating scale (KmSWN-10), which derived from the 19-items of Korean modified version of Subjective Well-being under the neuroleptic treatment (KmSWN) scale. The assessments were administered at baseline, 2 weeks, 12 weeks and 24 weeks after switching to risperidone. Analysis were done using repeated measures of ANOVA. Pearson correlation analysis were also done to assess the correlation between KmSWN-10 and psychopathology and drug induced side effects.
Results: There were significant improvements on the scores of KmSWN-10 and reductions on the PANSS and UKU side effect rating scores during the treatment of risperidone. KmSWN-10 was negatively correlated with the total, negative and general psychopathology scales of PANSS at baseline, and also negatively corrleated with total, positive, negative, general psychopathology scales and depressive factor of PANSS scores and total UKU side effects rating scores at 24 weeks of treatment.
Conclusion: The results suggest that the maintenance treatment with risperidone positively affected on the subjective well-being of schizophrenic patients due to improvement of psychotic symptoms and decrement of side effects. KmSWN-10 may be more related with negative and general psychopathlogy scales of PANSS in this study.

참고문헌 (Reference)

1 윤진상, "항정신병약물 치료하에서 주관적 안녕감을 평가하는 한국형 척도의 개발" 39 : 987-998, 2000

2 신일선, "정신분열병 및 기타 정신증적 장애의 입원환자 치료에서 Olanzapine의 효과 : 유효성, 안정성 및 삶의 질" 대한정신약물학회 14 (14): 48-62, 2003

3 윤보현, "입원중인 정신분열병 환자에서 비전형 및 전형 항정신병약물에 대한 주관적인 반응" 대한생물치료정신의학회 8 (8): 298-304, 2002

4 Rifkin A, "리스페리돈 교체 투여 후 주관적 안녕감" 15 (15): 284-295, 2004

5 장세진, "건강통계자료 수집 및 측정의 표준화 연구" 대한예방의학회 121-159, 1993

6 van Putten T, "Why do schizophrenic patients refuse to take their drugs?" 31 : 67-72, 1974

7 Windgasen K, "Treatment with neuroleptics:the patients pers-pective" 86 : 405-410, 1992

8 Selten JP, "The subjective experience of negative symptoms:a self-rating scale" 34 : 192-197, 1993

9 Lidle PF, "The subjecctive experience of deficits in schizophrenia" 29 : 157-164, 1988

10 Jaeger J, "The measurement of sub-jective experience in schizophrenia:the subjective deficit syn-drome scale" 31 : 216-26, 1990

11 Lingjaerde O, "The UKU side effect rating scale" 76 (76): 1-100, 1987

12 American Psychiatric Asociation, "The Diagnosis and Statistical Manual of Mental Disorder" American Psychiatric Press 1994

13 Naber D, "Subjetive effects of neuroleptics predict compliance Prediction of Neuroleptic Treament out-come in Schizophrenia" 85-98, 1994

14 "Subjective well-being and quality of life un-der atypical antipsychotic treatment" 162 : 3-10, 2002

15 Kook SH, "Subjective wel-being of schizophrenic patients under neuroleptics and implications for clincial and sociodemographic characteristics objective psycho-pathology and motor side efects of neuroleptics. KPA 50th Ani-versary Conference" Seoul, Korean Psychological Asociation 1996

16 Awad AG, "Subjective response to neuroleptics in schizophrenia" 19 : 609-618, 1993

17 Awad AG, "Subjective response to neuroleptics and the quality of life:implications for treatment outcome" 380 : 27-32, 1994

18 van Puten T, "Subjective response to antipsychotic drugs" 38 : 187-190, 1981

19 "Should we consider mod distur-bance in schizophrenia as an important determinant of quality of life?" 60 (60): 23-29, 1999

20 Conley RR, "Risperidone side efects" 61 (61): 20-23, 2000

21 Bech P, "Rating Scale for Psychopathology Health Status and Quality of Life. A Compendium on Documentation in Acordance with the DSM-III-R and WHO systems" Berline, Springer-Verlag 402-404,

22 Schipper H, "Quality of life studies: definitions and conceptual isues. In: Silker B. editor. Quality of Life and Pharmacoeconomics in Clinical Trial,2nd ed ." Phila-delphia, Lippincot-Raven 1-23, 1996

23 "Quality of life in schizophrenia:long-term follow-up in 362 chronic Spanish schizophrenic out-patients undergoing risperidone maintenance treatment" 13 : 158-168, 1998

24 "Quality of life and schizophrenia: the impact of no-vel antipsychotic medications" 31 : 144-146, 1999

25 Lancet, "Quality of life and clinical trials (Editorial)" 346 : 1-2, 1995

26 "Patients satisfaction with antipsychotic drug the-rapy for schizophrenia Clear perspectives-management is-sues in schizophrenia compliance and out-comes in schizophrenia" London (UK), AstraZeneca Pharma-ceuticals 7-1, 1999

27 Tollefson GD, "Olanzapine versus halo-peridol in the treatment of schizophrenia,schizoaffective and sc-hizophreniform disorders:results of an international collabora-tion study" 154 : 457-465, 1997

28 "New antipsychotics, compliance, qu-ality of life, and subjective tolerability - Are patients better off?" 49 : 297-302, 2004

29 Lader M, "Neuroleptic induced deficit syndrome:old problem,new challenge" 7 : 392-393, 1993

30 Emerich DF, "Neuroleptic dysphoria" 29 : 201-203, 1991

31 Harow M, "Neuroleptic depres-sion in schizophrenia" 30 : 844-848, 1991

32 Tollefson GD, "Negative symptoms:a path analytic approach to a double-blind,placebo- and haloperidol-controlled clinical trial with olazapine" 154 : 466-474, 1997

33 McNary SW, "Measuring subjective life satisfaction in persons with severe and persistent mental il-lness:a measurement quality and structural model analysis" 9 : 503-507, 1997

34 Lehman AF, "Measuring of quality of life among persons with severe and persistent mental disorders" 31 : 78-8, 1996

35 "Judging of quality of life of individuals with severe mental disorders:patient self-report versus provider perspectives" 153 : 497-502, 1996

36 "Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?" 49 : 285-289, 2004

37 "Influence of novel and conventional antipsychotic medication on subjective quality of life" 26 : 131-136, 2001

38 Naber D, "Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs" 50 : 79-88, 2001

39 Marder SR, "Facilitating compliance with antipsychotic medica-ion" 59 (59): 2-25, 1998

40 "Evaluating quality-of-life measures for clinical trials in Germany" 12 : 91-105, 1991

41 Fenton WS, "Determinants of medica-tion compliance in schizophrenia: empirical and clinical fin-dings" 23 : 637-651, 1998

42 Garavan J, "Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitude to medication and insight" 39 : 15-219, 1998

43 Voruganti L, "Comparative evaluation of conventional and novel antipsy-chotic drugs with reference to their subjective tolerability,side efect profile and impact on quality of life" 43 : 135-145, 2000

44 "Characterizing quality of life among patients with chronic mental illnes: a critical examination of the self-report methodology" 154 : 99-105, 1997

45 Naber D, "Atypische Neuroleptika in der Behandlung Schizophrener Patienten" Uni-Med, Brenen 1999

46 van Putten T, "Akinetic depresion in schizophrenia" 1101-1107, 1978

47 Wise RA, "Advances in Neuropsychiatry and Psychopharmacology" 323-331, 1991

48 Naber D, "A self-rating to measure subjective effects of neurolep-tic drugs relationship to objective psychopathology quality of life and other clinical variables" 10 : 133-138, 1995

49 Simpson GM, "A rating scale for extrapyramidal side efects" 11-19, actapsychiatrscand1970

50 "A Conceptual model of quality of life in schizophrenia:description and preliminary clinical validation" 6 : 21-26, 1997